ESTRO 2025 - Abstract Book

S2078

Clinical - Urology

ESTRO 2025

Results: From 11/2023 to 10/2024 twelve Pca patients with a median age of 76.9 (67.2-81.2) years were enrolled. Three were HR, 5 UIR, and 4 favorable intermediate-risk. Median initial PSA was 8.68 (2.9-18.15) ng/ml, one patient was ISUP grade 5, two patients 4, one patient 3, and 8 patients 2. Three patients presented grade (G)2 genito-urinary toxicity, and 7 G1. Six patients presented G1 gastro-intestinal toxicity. Conclusion: No G3 toxicity was recorded in the first 12 patients, so we can consider the first step of the trial as achieved; patients enrollment will continue. References: 1. Greco C, et al. Safety and Efficacy of Virtual Prostatectomy with Single-Dose Radiotherapy in Patients with Intermediate-Risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol 2022; 7(5):700-708. 2. Zilli T, et al. ONE SHOT- single shot radiotherapy for localized prostate cancer: 18 months results of a single arm, multicenter phase I/II trial. Radiother Oncol 2024; 194:110181 3. Arcangeli S, et al. Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study. Int J Radiat Oncol Biol Phys 2024; 120 (5): 1394-1403 Keywords: Urethral-sparing, one day prostate SBRT